Document Detail


Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis.
MedLine Citation:
PMID:  18713784     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Defining the remission criteria of rheumatoid arthritis (RA) remains a critical issue. Markers of synovium activity, urinary glucosyl-galactosyl-pyridinoline (Glc-Gal-PYD) and of cartilage destruction, urinary C-terminal crosslinking telopeptide of type II collagen (CTX-II) have been shown to reflect disease activity and joint damage progression in RA. METHODS: The prospective study cohort comprised 66 RA patients treated with infliximab and methotrexate and 76 healthy controls. Measurements of urinary Glc-Gal-PYD and CTX-II were performed at baseline and at 1 year of infliximab therapy. RESULTS: At baseline, urinary Glc-Gal-PYD and CTX-II levels were increased in patients with RA and correlated with modified Sharp scores and progression of joint damage. Patients with more progressive joint destruction had higher Glc-Gly-PYD and CTX-II baseline levels. CONCLUSION: These markers reflected bone erosion evolution and might be useful for treatment monitoring and evaluation of RA. Markers remained high even in clinical responders after infliximab, suggesting persistence of synovitis.
Authors:
H Marotte; E Gineyts; P Miossec; P D Delmas
Related Documents :
2480754 - Serological abnormalities, including common idiotype pr4, in families with rheumatoid a...
22016484 - Fraction of exhaled nitric oxide in patients with acute eosinophilic pneumonia.
759244 - Juvenile-onset diabetes hla-a, -b, -c, and -dr alloantigens.
12429534 - Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status...
24557334 - Liver involvement in patients with brucellosis: results of the marmara study.
11053724 - Effect of concomitant digoxin and carvedilol therapy on mortality and morbidity in pati...
Publication Detail:
Type:  Journal Article     Date:  2008-08-19
Journal Detail:
Title:  Annals of the rheumatic diseases     Volume:  68     ISSN:  1468-2060     ISO Abbreviation:  Ann. Rheum. Dis.     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-06-15     Completed Date:  2009-06-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372355     Medline TA:  Ann Rheum Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  1197-200     Citation Subset:  IM    
Affiliation:
Hospices Civils de Lyon-bioMérieux Research Unit on Rheumatoid Arthritis, Hospital Edouard Herriot, Lyon, France. hubert.marotte@laposte.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / therapeutic use*
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / drug therapy*,  urine
Biological Markers / metabolism
Collagen Type II / metabolism
Cross-Linking Reagents
Disaccharides / metabolism
Female
Humans
Male
Methotrexate / therapeutic use*
Middle Aged
Prospective Studies
Pyridines / metabolism
Synovial Membrane / metabolism*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/Biological Markers; 0/Collagen Type II; 0/Cross-Linking Reagents; 0/Disaccharides; 0/Pyridines; 0/alpha-D-glucopyranosyl-(1-2)-beta-D-galactopyranosyl-O-pyridinoline; 0/infliximab; 59-05-2/Methotrexate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Deoxyspergualin in relapsing and refractory Wegener's granulomatosis.
Next Document:  Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and...